DDInter1623 DDInter131
Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Rotavirus vaccine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Rotavirus vaccine {u} may lead to a major life threatening interaction when taken with {v} Carmustine
Rotavirus vaccine {u} may lead to a major life threatening interaction when taken with {v} Sarilumab
Rotavirus vaccine may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Rotavirus vaccine may lead to a major life threatening interaction when taken with Carmustine
Rotavirus vaccine may lead to a major life threatening interaction when taken with Sarilumab